by The global biopsy needle market size was estimated at USD 1.30 billion in 2023 and is predicted to rise around USD 2.60 billion by 2033, growing at a CAGR of 7.17% from 2024 to 2033.
Key Points
- The North America biopsy needle market size surpassed USD 520 million in 2023 and is predicted to hit around USD 1,030 million by 2033.
- North America dominated the global biopsy needle market with the largest market share of 39.7% in 2023.
- Asia Pacific is considered to register the fastest growth with a significant CAGR during the forecast period.
- By-product, the biopsy needle guns segment has held the largest share of 62% in 2023.
- By application, the cancer segment has accounted largest market share of 46% in 2023.
- By end-user, the hospitals segment has registered the largest market share of 58% in 2023.
The biopsy needle market is a dynamic and expanding segment within the global medical devices industry, driven by the increasing prevalence of chronic diseases such as cancer, rising demand for minimally invasive diagnostic procedures, and advancements in medical technology. Biopsy needles are essential tools used by healthcare professionals to obtain tissue samples from patients for diagnostic purposes, aiding in the diagnosis and staging of various diseases, particularly cancer. The market includes various types of biopsy needles, such as core needle biopsies, fine needle aspiration biopsies, vacuum-assisted biopsies, and image-guided biopsies. Each type serves specific diagnostic needs and is chosen based on the condition being investigated and the location of the tissue.
The global biopsy needle market is expected to grow significantly in the coming years, with increasing awareness of early disease detection and a rising geriatric population being primary factors driving the market. The market is also influenced by ongoing research and development activities aimed at improving the safety and efficacy of biopsy procedures.
Get a Sample: https://www.precedenceresearch.com/sample/4085
Growth Factors
Prevalence of Chronic Diseases
One of the key growth factors for the biopsy needle market is the rising prevalence of chronic diseases, particularly cancer. As cancer cases continue to increase globally, there is a growing need for accurate diagnostic procedures, including biopsies, to detect and monitor the progression of the disease. This demand drives the adoption of biopsy needles.
Technological Advancements
Advancements in medical technology have led to the development of more efficient and precise biopsy needles. These innovations include the use of image-guided techniques such as ultrasound, CT, and MRI, which enhance the accuracy of biopsy procedures and reduce complications. Additionally, new biopsy needle designs offer improved safety and patient comfort.
Minimally Invasive Procedures
Minimally invasive diagnostic procedures have gained popularity due to their benefits, such as reduced pain, faster recovery times, and fewer complications. Biopsy needles play a crucial role in these procedures, as they enable tissue sampling with minimal invasiveness. This trend contributes to the growth of the biopsy needle market.
Increasing Geriatric Population
The global geriatric population is growing, leading to a higher incidence of age-related diseases such as cancer. Older adults often require diagnostic procedures for disease detection, further driving the demand for biopsy needles.
Region Insights
North America
North America is expected to hold a significant share of the biopsy needle market, driven by the region’s well-established healthcare infrastructure, high healthcare expenditure, and increasing prevalence of chronic diseases. The United States, in particular, is a major market for biopsy needles due to its advanced medical facilities and ongoing research in cancer diagnosis and treatment.
Europe
Europe is another major market for biopsy needles, with countries such as Germany, the United Kingdom, and France at the forefront. The region’s strong healthcare system, aging population, and focus on early disease detection contribute to the market’s growth.
Asia-Pacific
The Asia-Pacific region is anticipated to experience substantial growth in the biopsy needle market, owing to the rising prevalence of chronic diseases, increasing healthcare awareness, and improving healthcare infrastructure. Countries such as China, India, and Japan are key markets within the region.
Latin America
Latin America is also expected to witness growth in the biopsy needle market due to increasing healthcare investments and awareness of early disease detection. Brazil and Mexico are notable markets in this region.
Middle East and Africa
The Middle East and Africa region has potential for growth in the biopsy needle market, particularly in countries with improving healthcare infrastructure. However, challenges such as limited access to advanced medical technologies may hinder rapid market expansion.
Biopsy Needle Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 7.17% |
| Global Market Size in 2023 | USD 1.30 Billion |
| Global Market Size in 2024 | USD 1.39 Billion |
| Global Market Size by 2033 | USD 2.60 Billion |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Product, By Application, and By End-use |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Drivers
Growing Need for Accurate Diagnostics
The demand for accurate and reliable diagnostic methods is a key driver of the biopsy needle market. Biopsy procedures provide essential information for diagnosing various diseases, particularly cancer, and help guide treatment decisions.
Preference for Minimally Invasive Techniques
Healthcare providers and patients increasingly prefer minimally invasive diagnostic procedures due to their benefits, such as reduced recovery times and lower risks of complications. Biopsy needles play a central role in these procedures, driving market growth.
Rising Healthcare Expenditure
As healthcare expenditure increases globally, there is greater investment in advanced medical devices and diagnostic tools. This trend supports the adoption of biopsy needles and other diagnostic devices.
Technological Innovations
Ongoing research and development in medical technology have led to innovative biopsy needle designs, such as vacuum-assisted and image-guided biopsies. These innovations enhance the safety and accuracy of biopsy procedures and drive market growth.
Challenges
High Costs
The cost of biopsy needles, particularly those with advanced features, can be a barrier to adoption in certain regions or healthcare settings. High costs may limit access to these devices, especially in low- and middle-income countries.
Risk of Complications
While biopsy procedures are generally safe, there is a risk of complications such as bleeding, infection, or damage to surrounding tissues. These risks may discourage some patients from undergoing biopsy procedures.
Regulatory Hurdles
The medical devices industry is subject to stringent regulations, which can slow down the introduction of new products to the market. Regulatory approval processes can be time-consuming and costly.
Opportunities
Growing Awareness of Early Detection
As awareness of the importance of early disease detection continues to rise, there is increasing demand for accurate diagnostic procedures, including biopsies. This trend presents opportunities for growth in the biopsy needle market.
Emerging Markets
Emerging markets such as Asia-Pacific, Latin America, and parts of Africa offer significant growth opportunities for the biopsy needle market. As healthcare infrastructure improves and healthcare awareness increases, the adoption of biopsy needles is expected to rise.
Collaboration and Partnerships
Collaboration between medical device manufacturers and healthcare providers can lead to the development of innovative biopsy needles and diagnostic tools. These partnerships can help bring new products to market and drive market growth.
Read Also: Agricultural Biologicals Market Size to Rake USD 39.59 Bn by 2033
Recent Developments
- In 2022, Cambridge Enterprise introduced their biopsy device named ‘CamPROBE’. The prostate biopsy device aims to reduce the risks related to conventional transrectal biopsies.
- In 2022, Mammatome introduced their dual-core biopsy system which marked their first step in the core biopsy market. The device reduces the vibrations and needle movements and helps to enhance the patient experience.
- In 2022, Limaca Medical received its breakthrough device through the FDA for its Precision-GI endoscopic ultrasound biopsy needle. The invention aims to reduce issues like blood contamination, tissue fragmentation, and less collection of sample quantity during the entire procedure.
- In 2021, Hologic Inc. acquired a company named Somatex Technologies for 64 million, aiming to increase the treatment offerings for breast cancer.
Biopsy Needle Market Companies
- Becton
- Medtronic Plc
- Cardinal Health
- Hologic Inc
- Olympus Corporation
- Argon Medical Devices Inc
- Devicor Medical Products, Inc
- B. Braun Melsungen AG
- Cook Group Incorporated
- Boston Scientific Corporation
- FUJIFILM Holdings Corporation
- Dickinson and Company
- Stryker Corporation
- INRAD, Inc
Segments Covered in the Report
By Product
- Biopsy Needle Guns
- Vacuum-assisted Biopsy Devices
- Fine Needle Aspiration Biopsy
- Core Needle Biopsy Devices
- Biopsy Needles
- Disposable
- Reusable
By Application
- Cancer
- Breast
- Lung
- Prostate
- Colon
- Stomach
- Liver
- Other cancer
- Autoimmune Disorder
- Infectious Diseases
- Others
By End-use
- Hospitals
- Ambulatory Surgical Centers
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
